PT2411395E - Derivados de furopirimidinadiona como moduladores de trpa1 - Google Patents
Derivados de furopirimidinadiona como moduladores de trpa1Info
- Publication number
- PT2411395E PT2411395E PT107160509T PT10716050T PT2411395E PT 2411395 E PT2411395 E PT 2411395E PT 107160509 T PT107160509 T PT 107160509T PT 10716050 T PT10716050 T PT 10716050T PT 2411395 E PT2411395 E PT 2411395E
- Authority
- PT
- Portugal
- Prior art keywords
- furopyrimidinedione
- derivatives
- trpa1 modulators
- trpa1
- modulators
- Prior art date
Links
- 101100482465 Caenorhabditis elegans trpa-1 gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN665MU2009 | 2009-03-23 | ||
| US17135509P | 2009-04-21 | 2009-04-21 | |
| IN2213MU2009 | 2009-09-23 | ||
| US25199409P | 2009-10-15 | 2009-10-15 | |
| IN2906MU2009 | 2009-12-16 | ||
| US29447010P | 2010-01-12 | 2010-01-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2411395E true PT2411395E (pt) | 2013-06-06 |
Family
ID=42780205
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT107160509T PT2411395E (pt) | 2009-03-23 | 2010-03-22 | Derivados de furopirimidinadiona como moduladores de trpa1 |
| PT13002731T PT2634191E (pt) | 2009-03-23 | 2010-03-23 | Processo para preparar derivados de tienopirimidinadiona |
| PT107517120T PT2411396E (pt) | 2009-03-23 | 2010-03-23 | Derivados de tienopirimidinadiona como moduladores de trpa1 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT13002731T PT2634191E (pt) | 2009-03-23 | 2010-03-23 | Processo para preparar derivados de tienopirimidinadiona |
| PT107517120T PT2411396E (pt) | 2009-03-23 | 2010-03-23 | Derivados de tienopirimidinadiona como moduladores de trpa1 |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US20120178766A1 (https=) |
| EP (3) | EP2411395B1 (https=) |
| JP (2) | JP2012521406A (https=) |
| KR (2) | KR20110128898A (https=) |
| CN (3) | CN102361874A (https=) |
| AP (1) | AP2948A (https=) |
| AU (2) | AU2010227225A1 (https=) |
| BR (2) | BRPI1013705A2 (https=) |
| CA (2) | CA2756535A1 (https=) |
| DK (3) | DK2411395T3 (https=) |
| EA (2) | EA201190138A1 (https=) |
| ES (3) | ES2424341T3 (https=) |
| HU (1) | HUE024538T2 (https=) |
| IL (2) | IL215177A (https=) |
| MX (1) | MX2011009822A (https=) |
| PE (2) | PE20120834A1 (https=) |
| PL (3) | PL2411395T3 (https=) |
| PT (3) | PT2411395E (https=) |
| SG (4) | SG174398A1 (https=) |
| SI (3) | SI2411395T1 (https=) |
| WO (2) | WO2010109329A1 (https=) |
| ZA (2) | ZA201107649B (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2411393T1 (sl) | 2009-03-23 | 2014-03-31 | Glenmark Pharmaceuticals S.A. | Kondenzirani pirimidin-dionski derivati kot TRPA 1 modulatorji |
| EP2411395B1 (en) | 2009-03-23 | 2013-05-29 | Glenmark Pharmaceuticals S.A. | Furopyrimidinedione derivatives as trpa1 modulators |
| PE20140234A1 (es) * | 2010-12-20 | 2014-03-08 | Glenmark Phamaceuticals S A | Compuestos de 2-amino-4-ariltiazol como antagonistas de trpa1 |
| EP2520566A1 (en) | 2011-05-06 | 2012-11-07 | Orion Corporation | New Pharmaceutical Compounds |
| CA2836856A1 (en) * | 2011-06-13 | 2012-12-20 | Glenmark Pharmaceuticals, S.A. | Treatment of respiratory disorders using trpa1 antagonists |
| WO2012176105A1 (en) | 2011-06-22 | 2012-12-27 | Glenmark Pharmaceuticals Sa | Pharmaceutical composition comprising a trpa1 antagonist and a leukotriene receptor antagonist |
| BR112013031820A2 (pt) * | 2011-06-22 | 2016-12-13 | Glenmark Pharmaceutical S A | composições farmacêuticas, incluindo para administração oral e por inalação, usos de quantidade sinergicamente eficaz de antagonista trpa1 e métodos para tratar distúrbios respiratórios e para melhorar a função pulmonar |
| US20140148423A1 (en) * | 2011-07-25 | 2014-05-29 | Glenmark Pharmaceuticals S.A. | Pharmaceutical composition comprising a trpa1 antagonist and a steroid |
| EP2787991A1 (en) | 2011-12-05 | 2014-10-15 | Glenmark Pharmaceuticals S.A. | Pharmaceutical composition comprising a trpa1 antagonist and an anticholinergic agent |
| SG11201408093PA (en) * | 2012-06-08 | 2015-01-29 | Glenmark Pharmaceuticals Sa | Amides of 2-amino-4-arylthiazole compounds and their salts |
| PT2903965T (pt) | 2012-10-01 | 2017-06-06 | Orion Corp | Derivados de n-prop-2-inilcarboxamida e sua utilização como antagonistas de trpa1 |
| EP3010489A1 (en) | 2013-06-20 | 2016-04-27 | Glenmark Pharmaceuticals S.A. | Nanoparticulate formulation comprising a trpa1 antagonist |
| EP3057583A2 (en) | 2013-10-15 | 2016-08-24 | Glenmark Pharmaceuticals S.A. | Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent |
| JP6573968B2 (ja) * | 2014-08-11 | 2019-09-11 | ハイドラ バイオサイエンシズ インコーポレイテッドＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． | ＴＲＰＣ５調節因子としての、精神神経障害の処置のためのチエノおよびフロ［２，３−ｄ］ピリミジン−２，４［１Ｈ，３Ｈ］−ジオン誘導体 |
| WO2016023830A1 (en) * | 2014-08-11 | 2016-02-18 | Hydra Biosciences, Inc. | Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives |
| WO2016023825A1 (en) * | 2014-08-11 | 2016-02-18 | Hydra Biosciences, Inc. | Pyrido[3,4-d]pyrimidine-2,4(1h,3h)-dione derivatives |
| JP6667092B2 (ja) * | 2014-08-11 | 2020-03-18 | ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ | ピロロ［３，２−ｄ］ピリミジン−２，４（３Ｈ，５Ｈ）−ジオン誘導体 |
| WO2016028325A1 (en) | 2014-08-22 | 2016-02-25 | Duke University | Trpa1 and trpv4 inhibitors and methods of using the same for organ-specific inflammation and itch |
| WO2016042501A1 (en) * | 2014-09-16 | 2016-03-24 | Glenmark Pharmaceuticals S.A. | Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic pain |
| US11229628B2 (en) | 2015-01-09 | 2022-01-25 | Duke University | TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch |
| WO2017060488A1 (en) | 2015-10-09 | 2017-04-13 | Almirall, S.A. | New trpa1 antagonists |
| WO2017064068A1 (en) | 2015-10-14 | 2017-04-20 | Almirall, S.A. | New trpa1 antagonists |
| CN109310683A (zh) * | 2016-04-07 | 2019-02-05 | 杜克大学 | 用于消毒和麻醉的trpv4和trpa1的小分子双重抑制剂 |
| WO2018162607A1 (en) * | 2017-03-07 | 2018-09-13 | F. Hoffmann-La Roche Ag | Oxadiazole transient receptor potential channel inhibitors |
| CN109422749B (zh) * | 2017-08-21 | 2023-01-24 | 重庆医药工业研究院有限责任公司 | 一种抑制单羧酸转运蛋白的嘧啶二酮衍生物 |
| JP7612682B2 (ja) | 2019-10-15 | 2025-01-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規なテトラゾール |
| CN116348471B (zh) * | 2020-10-14 | 2025-10-31 | 勃林格殷格翰国际有限公司 | 作为trpa1抑制剂的四唑衍生物 |
| AU2021363101A1 (en) * | 2020-10-14 | 2023-03-23 | Boehringer Ingelheim International Gmbh | Tetrazole derivatives as TRPA1 inhibitors |
| CN116940575A (zh) * | 2021-02-23 | 2023-10-24 | 深圳市康哲药业有限公司 | 噻吩并嘧啶二酮类化合物及其应用 |
| AU2022257269A1 (en) | 2021-04-14 | 2023-08-17 | Boehringer Ingelheim International Gmbh | 3H,4H-THIENO[2,3-d]PYRIMIDIN-4-ONE DERIVATIVES AS TRPA1 INHIBITORS |
| CN114671875A (zh) * | 2022-04-27 | 2022-06-28 | 成都施贝康生物医药科技有限公司 | 新型二氢嘧啶类化合物、异构体或盐及其制备方法和用途 |
| CN114656480B (zh) * | 2022-04-27 | 2024-01-26 | 成都施贝康生物医药科技有限公司 | 噻吩并嘧啶类化合物、异构体或盐及其制备方法和用途 |
| WO2025264860A2 (en) | 2024-06-18 | 2025-12-26 | Yale University | Methods of treating post-covid airway disease |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2248231A1 (de) | 1972-10-02 | 1974-04-11 | Basf Ag | 3-aminoisothiazolo eckige klammer auf 3,4-d eckige klammer zu pyrimidine |
| SE9701398D0 (sv) | 1997-04-15 | 1997-04-15 | Astra Pharma Prod | Novel compounds |
| SE9702001D0 (sv) * | 1997-05-28 | 1997-05-28 | Astra Pharma Prod | Novel compounds |
| DE69912618T2 (de) * | 1998-08-28 | 2004-10-28 | Astrazeneca Ab | NEUE THIENO[2,3-d]PYRIMIDINDIONE, VERFAHREN FÜR IHRE HERSTELLUNG UND IHRE VERWENDUNG IN DER THERAPIE |
| ES2193839B1 (es) * | 2001-06-22 | 2005-02-16 | Almirall Prodesfarma, S.A. | Nuevos derivados de 6-fenildihidropirrolpirimidindiona. |
| GB0118479D0 (en) * | 2001-07-28 | 2001-09-19 | Astrazeneca Ab | Novel compounds |
| AU2003253165A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Pyrimidine fused bicyclic metalloproteinase inhibitors |
| AR043057A1 (es) * | 2002-10-30 | 2005-07-13 | Vertex Pharma | Compuestos derivados de piridintiazoles como inhibidores de la quinasa rock y otras proteinas quinasa |
| US6890923B2 (en) * | 2002-12-16 | 2005-05-10 | Astrazeneca Ab | Compounds |
| WO2004055054A1 (en) | 2002-12-18 | 2004-07-01 | Novartis Ag | Anktm1, a cold-activated trp-like channel expressed in nociceptive neurons |
| SE0300119D0 (sv) * | 2003-01-17 | 2003-01-17 | Astrazeneca Ab | Novel compounds |
| EP1657238A4 (en) | 2003-08-22 | 2008-12-03 | Takeda Pharmaceutical | CONDENSATE PYRIMIDINE DERIVATIVE AND ITS USE |
| WO2005077959A1 (en) * | 2004-02-11 | 2005-08-25 | Smithkline Beecham Corporation | Pth agonists |
| WO2005089206A2 (en) | 2004-03-13 | 2005-09-29 | Irm Llc | Modulators of ion channel trpa1 |
| EP1847541A4 (en) * | 2005-02-03 | 2009-12-30 | Takeda Pharmaceutical | CONDENSED PYRIMIDINE DERIVATIVE AND USE THEREOF |
| US20070032531A1 (en) * | 2005-08-04 | 2007-02-08 | Apogee Biotechnology Corporation | Sphingosine kinase inhibitors and methods of their use |
| CN101351463A (zh) * | 2005-11-08 | 2009-01-21 | 欧加农股份有限公司 | 用于治疗trpv1相关病症的2-(苯并咪唑-1-基)-n-(4-苯基噻唑-2-基)乙酰胺衍生物 |
| WO2007054480A1 (en) * | 2005-11-08 | 2007-05-18 | N.V. Organon | 2-(benzimidazol-1-yl)-acetamide biaryl derivatives and their use as inhibitors of the trpv1 receptor |
| US20070105920A1 (en) * | 2005-11-08 | 2007-05-10 | Akzo Nobel N.V. | 2-(Benzimidazol-1-Yl)-N-(4-phenylthiazol-2-yl) acetamide derivatives |
| AU2006327181A1 (en) | 2005-12-22 | 2007-06-28 | Hydra Biosciences, Inc. | TRPA1 inhibitors for treating pain |
| TW200800997A (en) | 2006-03-22 | 2008-01-01 | Astrazeneca Ab | Chemical compounds |
| AR065081A1 (es) | 2007-01-29 | 2009-05-13 | Xenon Pharmaceuticals Inc | Compuestos de quinazolinona y pirimidona fusionados y composicion farmaceutica |
| ES2609912T3 (es) | 2007-06-22 | 2017-04-25 | Hydra Biosciences, Inc. | Compuestos de 2,6-dioxo, -2,3-dihidro-1h-purina útiles para el tratamiento de trastornos relacionados con la actividad del canal trpa1 |
| WO2009002983A1 (en) * | 2007-06-25 | 2008-12-31 | Sandisk Corporation | Non-volatile storage with individually controllable shield plates between storage elements |
| US7951814B2 (en) | 2008-06-17 | 2011-05-31 | Glenmark Pharmaceuticals, S.A. | Quinazolinedione derivatives as TRPA1 modulators |
| WO2009158719A2 (en) | 2008-06-27 | 2009-12-30 | Hydra Biosciences, Inc. | Methods and compositions for treating disorders |
| UA103918C2 (en) | 2009-03-02 | 2013-12-10 | Айерем Элелси | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators |
| US8623880B2 (en) | 2009-03-23 | 2014-01-07 | Glenmark Pharmaceuticals S.A. | Fused pyrimidine-dione derivatives as TRPA1 modulators |
| EP2411395B1 (en) | 2009-03-23 | 2013-05-29 | Glenmark Pharmaceuticals S.A. | Furopyrimidinedione derivatives as trpa1 modulators |
| WO2010109328A1 (en) | 2009-03-23 | 2010-09-30 | Glenmark Pharmaceuticals, S.A. | Isothiazolo-pyrimidinedione derivatives as trpa1 modulators |
| AR076332A1 (es) | 2009-04-21 | 2011-06-01 | Boehringer Ingelheim Int | Derivados heterociclicos de 5-alquinil-piridinas, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento y/o prevencion del cancer, procesos inflamatorios, autoinmunes, y/o infecciones. |
| AR078522A1 (es) | 2009-10-15 | 2011-11-16 | Lilly Co Eli | Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis |
| ES2426407T3 (es) | 2009-10-15 | 2013-10-23 | Pfizer Inc. | Compuestos de pirrolo[2,3-d]pirimidina |
| US8440710B2 (en) | 2009-10-15 | 2013-05-14 | Hoffmann-La Roche Inc. | HSL inhibitors useful in the treatment of diabetes |
| US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| ES2539170T3 (es) | 2010-01-12 | 2015-06-26 | Ab Science | Inhibidores de quinasas de oxazol |
| DK2483255T3 (da) | 2010-07-13 | 2014-01-20 | Novartis Ag | Oxazinderivater samt deres anvendelse ved behandling af neurologiske lidelser |
-
2010
- 2010-03-22 EP EP10716050.9A patent/EP2411395B1/en not_active Not-in-force
- 2010-03-22 JP JP2012501412A patent/JP2012521406A/ja active Pending
- 2010-03-22 ES ES10716050T patent/ES2424341T3/es active Active
- 2010-03-22 EA EA201190138A patent/EA201190138A1/ru unknown
- 2010-03-22 KR KR1020117022604A patent/KR20110128898A/ko not_active Withdrawn
- 2010-03-22 WO PCT/IB2010/000840 patent/WO2010109329A1/en not_active Ceased
- 2010-03-22 US US13/257,280 patent/US20120178766A1/en not_active Abandoned
- 2010-03-22 SG SG2011066446A patent/SG174398A1/en unknown
- 2010-03-22 SI SI201030233T patent/SI2411395T1/sl unknown
- 2010-03-22 PL PL10716050T patent/PL2411395T3/pl unknown
- 2010-03-22 CA CA2756535A patent/CA2756535A1/en not_active Abandoned
- 2010-03-22 PE PE2011001704A patent/PE20120834A1/es not_active Application Discontinuation
- 2010-03-22 PT PT107160509T patent/PT2411395E/pt unknown
- 2010-03-22 AU AU2010227225A patent/AU2010227225A1/en not_active Abandoned
- 2010-03-22 CN CN2010800134701A patent/CN102361874A/zh active Pending
- 2010-03-22 DK DK10716050.9T patent/DK2411395T3/da active
- 2010-03-22 SG SG2012069472A patent/SG184767A1/en unknown
- 2010-03-22 BR BRPI1013705A patent/BRPI1013705A2/pt not_active IP Right Cessation
- 2010-03-23 MX MX2011009822A patent/MX2011009822A/es unknown
- 2010-03-23 DK DK10751712.0T patent/DK2411396T3/da active
- 2010-03-23 BR BRPI1009381A patent/BRPI1009381B8/pt active IP Right Grant
- 2010-03-23 DK DK13002731T patent/DK2634191T3/en active
- 2010-03-23 PL PL10751712T patent/PL2411396T3/pl unknown
- 2010-03-23 AU AU2010227230A patent/AU2010227230B2/en not_active Ceased
- 2010-03-23 EA EA201190139A patent/EA022029B1/ru unknown
- 2010-03-23 KR KR1020117022603A patent/KR101524337B1/ko not_active Expired - Fee Related
- 2010-03-23 JP JP2012501414A patent/JP5612070B2/ja not_active Expired - Fee Related
- 2010-03-23 PE PE2011001705A patent/PE20120775A1/es active IP Right Grant
- 2010-03-23 AP AP2011005889A patent/AP2948A/xx active
- 2010-03-23 PT PT13002731T patent/PT2634191E/pt unknown
- 2010-03-23 WO PCT/IB2010/000930 patent/WO2010109334A2/en not_active Ceased
- 2010-03-23 SG SG2012069530A patent/SG184769A1/en unknown
- 2010-03-23 HU HUE13002731A patent/HUE024538T2/hu unknown
- 2010-03-23 EP EP10751712.0A patent/EP2411396B1/en active Active
- 2010-03-23 ES ES13002731.1T patent/ES2532386T3/es active Active
- 2010-03-23 ES ES10751712T patent/ES2424342T3/es active Active
- 2010-03-23 EP EP13002731.1A patent/EP2634191B1/en active Active
- 2010-03-23 US US12/936,451 patent/US8507503B2/en not_active Expired - Fee Related
- 2010-03-23 PT PT107517120T patent/PT2411396E/pt unknown
- 2010-03-23 CA CA2756536A patent/CA2756536C/en active Active
- 2010-03-23 PL PL13002731T patent/PL2634191T3/pl unknown
- 2010-03-23 SG SG2011066503A patent/SG174404A1/en unknown
- 2010-03-23 SI SI201030231T patent/SI2411396T1/sl unknown
- 2010-03-23 CN CN201080013463.1A patent/CN102361877B/zh not_active Expired - Fee Related
- 2010-03-23 CN CN201310628814.5A patent/CN103755720B/zh not_active Expired - Fee Related
- 2010-03-23 SI SI201030891T patent/SI2634191T1/sl unknown
-
2011
- 2011-09-15 IL IL215177A patent/IL215177A/en not_active IP Right Cessation
- 2011-09-15 IL IL215175A patent/IL215175A/en active IP Right Grant
- 2011-10-19 ZA ZA2011/07649A patent/ZA201107649B/en unknown
- 2011-10-19 ZA ZA2011/07650A patent/ZA201107650B/en unknown
-
2013
- 2013-06-25 US US13/925,975 patent/US8987278B2/en active Active
-
2015
- 2015-02-12 US US14/620,721 patent/US9474758B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2411395E (pt) | Derivados de furopirimidinadiona como moduladores de trpa1 | |
| MX2015005286A (es) | Procedimiento para la preparación de derivados del ácido biliar. | |
| PH12012500634A1 (en) | Processes for preparing of glucopyranosyl -substituted benzyl -benzene derivatives | |
| MD20180040A2 (ro) | Inhibitori ai virusului hepatic C | |
| MY164776A (en) | Heterocyclic compound | |
| MX2012003343A (es) | Proceso para preparar compuestos azabiciclicos. | |
| TN2012000248A1 (en) | Novel spiropiperidine compounds | |
| PH12015501226A1 (en) | Crystalline 6,7-unsaturated-7-carbamoyl morphinane derivative, and method for producing the same | |
| WO2010150211A3 (en) | Use of derivatives of indoles for the treatment of cancer | |
| HK1223541A1 (zh) | 色甘酸衍生物以及成像和治疗的相关方法 | |
| MX2011011776A (es) | Nuevos profarmacos de triptolite. | |
| IL209209A0 (en) | Process of preparing derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid | |
| IN2013MN02170A (https=) | ||
| IN2012DN01292A (https=) | ||
| MX2011009898A (es) | Proceso para la obtencion de derivados de acido propionico. | |
| IN2014CN04449A (https=) | ||
| MX2012001411A (es) | Proceso para la preparacion de derivados de acido 1-(2-halobifenil-4-il)-ciclopropanocarboxilico. | |
| MX2011007978A (es) | Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable. | |
| IN2014MN00971A (https=) | ||
| WO2012140490A3 (en) | Processes for preparing pitavastatin calcium | |
| MX2014009084A (es) | Derivados de pirimidooxazocina como inhibidores de mtor. | |
| MX2013004193A (es) | Procedimiento para la preparacion de derivados de acido 3-(6-amino-piridin-3-il)-2-acrilico. | |
| IN2012DN02000A (https=) | ||
| MY181791A (en) | Process for the preparation of propionic acid derivatives | |
| MX2013004425A (es) | Preparacion diastereoselectiva de los compuestos de biciclo [2.2.2] octan-2-ona. |